Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension
-
Add time:07/14/2019 Source:sciencedirect.com
BackgroundPulmonary arterial hypertension (PAH) is a chronic fatal disease. The treatment of PAH is less than ideal and the control is far from satisfactory worldwide. Vaccination provides a promising approach for treatment of PAH.
We also recommend Trading Suppliers and Manufacturers of 1-[(4E)-6-bromo-4-hydroxyimino-2,3-dihydroquinolin-1-yl]-2-methyl-prop an-1-one (cas 81892-48-0). Pls Click Website Link as below: cas 81892-48-0 suppliers
Prev:Overexpression of phosphorylated 4E-binding protein 1 and its clinicopathological significances in gastric cancer
Next:Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors07/15/2019
- Overexpression of phosphorylated 4E-binding protein 1 and its clinicopathological significances in gastric cancer07/13/2019
- Novel 9-(2-(1-arylethylidene)hydrazinyl)acridine derivatives: Target Topoisomerase 1 and growth inhibition of HeLa cancer cells07/12/2019
- Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway07/11/2019
